CKD Supplement Products, Reviewed

BOTTOM LINE

Same "adsorb in the gut" family as AST-120. Perhaps an adjunct for uremic-symptom care — but no evidence yet to expect better values.

Spherical carbon granules (Renaltec) adsorb uremic-toxin precursors (indoles) in the gut and pass them in stool. Being the same mechanistic family as Kremezin (AST-120), it faces the same question — "nice theory, but does it work in cats?" In-vitro and mechanistic data exist; feline clinical proof of better values or survival does not. That the human large trials of this family (AST-120) failed is another reason to keep expectations modest.

FACTS

Research

Toxin-precursor adsorption shown in vitro — no feline clinical outcomes (values or survival) proven

Track record

Launched in Europe around 2019; in Korea for a few years

Caution

Separate from other medications by 2 hours (common to all adsorbents)

Read the full fact-check →

BOTTOM LINE

Evidence that it lowers values is weak. Not harmful, but no reason to rank it above phosphorus control and hydration.

The product rides on the "enteric dialysis" hypothesis — gut bacteria degrading uremic toxins. Early small studies were manufacturer-affiliated, and an independent feline double-blind trial failed to reproduce the effect. It has survived 18 years because it is safe and gives caregivers the sense of doing something. On a limited budget, binders, hydration and diet come first.

FACTS

Research

Feline double-blind study (Rishniw 2011) failed to reproduce azotemia improvement

Track record

Launched 2006; 18+ years on the veterinary market

Caution

If the cold chain breaks, the capsule may contain dead bacteria

TYPES & INGREDIENTS

• 3 probiotic strains (E. thermophilus et al.)Toxin-degrading hypothesis — not reproduced in cats
• Psyllium huskFiber; amount undisclosed

BOTTOM LINE

The Azodyl verdict applies as-is. Harmless, but no reason to rank it above the basics — phosphorus, hydration, diet.

Another product of the "enteric dialysis" hypothesis — gut bacteria degrading uremic toxins (Kibow, the same lineage as Azodyl's strains). A few small human studies exist, all manufacturer-affiliated; feline clinical evidence does not. Everything said on the Azodyl card applies here — including the failure of independent verification for this family.

FACTS

Research

A few small manufacturer-affiliated human studies — no feline clinical evidence

Track record

Kibow Biotics (US); pet line extended from the human product

Caution

Requires refrigeration (live bacteria)

TYPES & INGREDIENTS

• Probiotic & prebiotic blendToxin-degrading hypothesis — unverified in cats

BOTTOM LINE

If stools have improved and giving it is no burden, it is fine to continue. There is not yet evidence to delay other treatment or spend heavily on it to lower kidney values.

Each sachet holds two bifidobacteria — B. bifidum BGN4 (27 billion CFU) and B. longum BORI (3 billion CFU). They are human strains from the Korean company Bifido, with well-documented safety (US FDA GRAS). The kidney evidence runs on two tracks. (1) In rats with kidney ischaemia-reperfusion injury (a model of acute injury progressing to chronic disease), BGN4 reduced inflammation and fibrosis in the gut and kidney, and a patent for improving kidney failure is based on it. (2) A study gave it to human haemodialysis patients for 3 months and measured inflammation markers. There is no study yet showing lower creatinine or uremic toxins in cats or dogs. Reports of "creatinine went down after starting it" are single uncontrolled observations that cannot be separated from changes in fluids, diet or season. Azodyl, from the same family, was promising at first but did not hold up in an independent feline study. So this product is best seen as a probiotic that helps gut health and stools; any kidney effect is still a possibility.

FACTS

Research

BGN4: less inflammation and fibrosis in a rat kidney-injury model; a 3-month inflammation study in human haemodialysis patients · no cat or dog studies

Track record

Korean product · strains (BGN4, BORI) listed as US FDA GRAS

Caution

If refusing the powder or capsule makes the cat eat less, it is a net loss — appetite comes first. No reason to stack it with other probiotics

TYPES & INGREDIENTS

• B. bifidum BGN4 (27 billion CFU)Less inflammation and fibrosis in a rat kidney-injury model; human haemodialysis inflammation study
• B. longum BORI (3 billion CFU)No kidney-specific evidence on its own — for gut balance

BOTTOM LINE

"Designed with AIM in mind" is not "an AIM drug." The real AIM therapeutic is still in trials; this product is an amino-acid/antioxidant blend borrowing the name.

AIM-protein research (Prof. Toru Miyazaki) — implicating AIM in feline kidney disease — is the most anticipated science in this field. But the actual AIM therapeutic born of that research is still in clinical trials, not on sale. Dr. Toru is a supplement: an amino-acid complex "designed with the AIM mechanism in mind," plus resveratrol and CoQ10. There is no clinical evidence this blend activates AIM or changes renal outcomes. Curious about AIM itself? Read our "New treatments" article — it draws the line between the science and the marketing.

FACTS

Research

AIM research (Prof. Miyazaki, U-Tokyo) is at the drug-development stage — no evidence this supplement activates AIM or improves outcomes

Track record

A few years on the Korean market · the actual AIM drug remains in clinical development

Caution

No safety concerns reported

TYPES & INGREDIENTS

• Amino-acid complexNo clinical evidence of AIM activation
• ResveratrolAntioxidant — extrapolated from in-vitro/other species
• Coenzyme Q10No feline evidence (see the ubiquinol entry)

Read the full fact-check →

BOTTOM LINE

Marketed as "backed by studies," but those studies have not cleared the verification bar. It may work, it may not — right now we do not know.

An amino-acid/peptide blend (AB070597) claimed to support kidney function. The cited studies are small, manufacturer-affiliated, and unreplicated by independent groups. That is not the same as "proven ineffective" — but it has not earned "effective" either. It appears safe, so trying it is your call if budget allows; it has no standing to replace the basics.

FACTS

Research

Only two small manufacturer-affiliated studies; no independent replication or solid controls

Track record

Launched in the 2010s

Caution

No safety concerns reported

TYPES & INGREDIENTS

• Amino-acid/peptide blend (AB070597)No independent verification

BOTTOM LINE

Some ingredients point the right way, but whether the amounts reach studied doses is the question. Its real value is convenience — one product standing in for several.

A one-jar blend of probiotics, prebiotics, chitosan (a phosphate binder) and B vitamins. Products like this must be judged by ingredient evidence, not product marketing — and by whether per-ingredient amounts reach studied doses. Buying single ingredients separately is usually surer on dosing; blends are a practical compromise to reduce pill count. ※ Ingredient list to be verified against the product label.

FACTS

Research

No clinical evidence for the product itself — only assessable through its individual ingredients

Track record

European veterinary supplement line, distributed in Korea

Caution

If already on a phosphate binder, check for overlapping binding ingredients

TYPES & INGREDIENTS

• Probiotics & prebioticsExtrapolated in the CKD context
• Chitosan / binding agentsBinding direction valid; check amounts
• B vitaminsWater-soluble vitamin replacement rationale